In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.

The objective of this study was to evaluate the activity of the fluoroquinolone, levofloxacin, against hospital isolates of bacteria. MICs of levofloxacin were determined for 2154 strains by agar dilution. Breakpoints for susceptibility testing were calculated using the agar diffusion technique with 5 micrograms discs. The activity of levofloxacin against nalidixic acid- and pefloxacin-susceptible Enterobacteriaceae (n = 668) was higher (MIC50/90 0.06-0.12 mg/L) than previously reported for ofloxacin. As seen with other fluoroquinolones, this activity was reduced against nalidixic acid-resistant and pefloxacin-intermediate and -resistant strains (MIC 1-8 mg/L). MICs for Pseudomonas aeruginosa (n = 104) were between 0.12 and 128 mg/L. Levofloxacin had good activity against nalidixic acid- and pefloxacin-susceptible Acinetobacter baumannii (n = 12; MIC 0.06-0.25 mg/L), but the activity was reduced against nalidixic acid- and pefloxacin-resistant strains (n = 80; MIC 1-32 mg/L). Haemophilus influenzae (n = 70), Haemophilus parainfluenzae (n = 47) and Moraxella catarrhalis (n = 64) were inhibited by low concentrations of levofloxacin (MICs 0.016-0.03 mg/L, 0.03-0.12 mg/L) and 0.03-0.12 mg/L, respectively). Clostridium perfringens (n = 23; MIC 0.25-1 mg/L) was more susceptible than Bacteroides fragilis (n = 60; MIC 0.5-4 mg/L). Levofloxacin showed superior activity compared with ofloxacin against methicillin-susceptible staphylococci (n = 107; MIC 0.03-0.5 mg/L); the resistant strains (MICs 2-32 mg/L) were usually also resistant to methicillin. Levofloxacin was less effective against enterococci (n = 105; MIC 1-32 mg/L), but streptococci (n = 192) and pneumococci (n = 129), including 58 penicillin-non-susceptible strains, were inhibited by low concentrations (MICs 0.5-2 mg/L). According to the regression curve, zone diameters were usually 20-22 mm, 17-19 mm and 15-16 mm for MICs of 1, 2 and 4 mg/L, respectively. In conclusion, this study, performed on a large number of strains, confirms the superior anti-bacterial activity of levofloxacin compared with ofloxacin, especially against pathogens isolated from respiratory tract infections.

[1]  M. Swartz.  Use of antimicrobial agents and drug resistance. , 1997, The New England journal of medicine.

[2]  M. Jacobs,et al.  Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. , 1997, Diagnostic microbiology and infectious disease.

[3]  I. Morrissey,et al.  The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. , 1997, The Journal of antimicrobial chemotherapy.

[4]  D. Fish,et al.  The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.

[5]  F. Goldstein,et al.  Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992–93 Western Europe and USA collaborative surveillance study , 1996 .

[6]  R. Jones.  Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. , 1996, The American journal of medicine.

[7]  G. Eliopoulos,et al.  Comparative in vitro activity of levofloxacin and ofloxacin against gram-positive bacteria. , 1996, Diagnostic microbiology and infectious disease.

[8]  M. Cormican,et al.  Susceptibility testing interpretive criteria for levofloxacin when testing respiratory pathogens, Haemophilus influenzae and Moraxella catarrhalis. , 1996, Diagnostic microbiology and infectious disease.

[9]  F. Tenover,et al.  In-vitro susceptibility of Streptococcus pneumoniae to the d- and l-isomers of ofloxacin: interpretive criteria and quality control limits. , 1996, The Journal of antimicrobial chemotherapy.

[10]  K. Thomson,et al.  Dissociated resistance among fluoroquinolones , 1994, Antimicrobial Agents and Chemotherapy.

[11]  G. Bodey,et al.  Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones , 1994, Antimicrobial Agents and Chemotherapy.

[12]  R. Davis,et al.  Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. , 1994, Drugs.

[13]  R. Jones,et al.  Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. , 1994, Journal of chemotherapy.

[14]  B. Foleno,et al.  In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin , 1992, Antimicrobial Agents and Chemotherapy.

[15]  L. Piddock,et al.  The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones. , 1988, The Journal of antimicrobial chemotherapy.

[16]  E. Bruck,et al.  National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.

[17]  B. Foleno,et al.  Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. , 1993, Chemotherapy.